GSK to buy RAPT Therapeutics for US$2.2 billion

GSK will buy RAPT Therapeutics for US$2.2 billion (HK$17.16 billion), the British drugmaker said on Tuesday, expanding its respiratory, immunology & inflammation offerings, led by the US firm's experimental drug for food allergies, ozureprubart.

The London-listed company will pay US$58.00 per RAPT share, with an upfront investment of US$1.9 billion, and the deal will give GSK global rights to the ozureprubart programme, excluding mainland China, Macau, Taiwan and Hong Kong.

Reuters